Summary Intratumoral induction of tumour necrosis factor (TNF) by administration of Bordetella pertussis vaccine (BPV) as compared with that by the agent OK-432 was investigated in mice. Two hours after such administration tumour tissues tested were resected from the mice, homogenised, and the TNF activities in the homogenate were assayed using a L-929 fibroblast assay. Intravenous injection of BPV into mice bearing the MM46 carcinoma resulted in a greater concentration of TNF in the tumour homogenate than in the serum. With OK-432, however, there was a greater concentration of TNF in the serum than in the tumour homogenates. A high level of intratumoral TNF induction by BPV was also observed in mice bearing Meth A fibrosarcoma or Lewis lung carcinoma. The therapeutic effect against the Meth A fibrosarcoma was in parallel with the intratumoral TNF activity. Intratumoral TNF activity is therefore believed to be a good index of therapeutic effect.
In 1975, Carswell et al. reported that the sera of endotoxin (LPS)-treated animals infected with Bacillus Calmette-Gu&rin (BCG) caused haemorrhagic necrosis of various tumours in mice without apparent side-effects in the host (Carswell et al., 1975) . The factor responsible for this activity in the serum was called tumour necrosis factor (TNF). TNF can be effectively induced by two-stage stimulation, priming with BCG and triggering with LPS. Both agents are derived from bacterial bodies. In previous studies we developed an experimental model for endogenous production of TNF which is clinically applicable, because various commercial preparations of biological response modifiers (BRM), mainly of bacterial origin, could be used as primers or triggers (Satoh et al., 1986a,b,c; Minagawa et al., 1987 Minagawa et al., , 1988 . With a combination of purified protein derivative (PPD) plus (bacterial body of Streptococcus sp.) or IFN-y plus OK-432 we achieved partial regression of lung and liver tumours in patients (Kato et al., 1985 (Kato et al., , 1987 . These clinical trials are in progress. A brief review of our work to date has been published (Soma et al., 1990) . With time, problems encountered in treating patients have led to recognition of the desirability of using a single agent in a simpler procedure in clinical trials.
In a previous paper, we reported that systemic administration of Bordetella pertussis vaccine (BPV) induced high TNF activity in the sera of mice when MAF or IFN-' was used as a primer (Minagawa et al., 1988) . With localised injection into tumour tissue, a single injection of BPV could induce intratumoral TNF activity.
In this paper, we report that BPV can also induce high intratumoral TNF activity when administered as a single systemic injection.
Materials and methods

Animals
Male C3H/He, female BALB/c and C57BL/6 mice, 4-7 weeks old, were purchased from Shizuoka Experimental Animal Farm (Shizuoka, Japan).
Cell line
A transformed cell line (L-929) originally derived from a C3H/He strain mouse was grown in Eagle's minimum essential medium (MEM; Nissui Seiyaku Co., Tokyo, Japan) supplemented with 5% fetal calf serum (FCS; Hyclone Laboratories, USA) and was passaged every 3 or 4 days.
Chemical reagents BPV which contained approximately 2 x 10'0 killed bacteria in 1 ml of saline was obtained from Chiba Serum Institute (Chiba, Japan) and OK-432, penicillin-and heat-treated lyophilised powder of Streptococcus pyogenes (Uchida et al., 1980) was from Chugai Seiyaku Co. (Tokyo, Japan).
Rabbit anti-murine TNF-a antiserum (anti-MuTNF Ab) was purchased from Genzyme (Boston, USA) and a monoclonal antibody against mouse macrophage (anti-macrophage Ab) was from Sera-Lab. (Sussex, UK). Recombinant murine interferon-y (Mu-IFN-'y) was kindly provided by Toray Industries Inc. (Tokyo, Japan).
TNF assay TNF activity of test samples was assayed using L-929 mouse fibroblasts in the presence of actinomycin D (1 ig ml-') by the method of Ruff and Gifford (1980) with minor modifications (Gatanga et al., 1985 (Gatanga et al., , 1989 involving the extrapolation assay (Treffers, 1956 injection is shown in Figure 1 . The intratumoral TNF activity reached a maximum (22 units g-) 1 h after BPV injection and then decreased, becoming negligible after 6 h. On the other hand, intratumoral TNF activity was barely detected at any time following OK-432 injection.
Therapeutic test The therapeutic effect of i.v. injection of BPV or OK-432 was investigated. The tumour diameters were measured at intervals following tumour inoculation. The result of BPV injection against Meth A fibrosarcoma is shown in Figure 2 and that of OK-432 in Figure 3 . BPV was more effective than OK-432 in the case of both single and multiple injection. Complete cure was achieved in 16.7% and 33.3% of mice by single and multiple injections of BPV respectively.
Neutralisation of intratumoral TNF activity by anti-MuTNF Ab Neutralisation of intratumoral TNF activity in MM46 and Meth A-bearing mice by anti-MuTNF Ab is shown in Table  III . In both cases, intratumoral TNF activities were completely neutralised with anti-MuTNF Ab.
Decrease in intraperitoneal TNF activity induced by the injection of MM46 carcinoma cells and BPV by antimacrophage antibody Decrease in intraperitoneal TNF activity by anti-macrophage Ab which recognises a Mac-I antigen on mononuclear phagocytes (Springer et al., 1979 ) is shown in Table IV . TNF activity was induced in the peritoneal fluid by the i.p. injection of MM46 tumour cells and BPV. TNF activity was reduced more than 90% by pretreatment with anti-macrophage Ab.
Effect of Mu-IFN-y on serum and intratumoral TNF induction Effect of Mu-IFN-'y on serum and intratumoral TNF induction in MM46-bearing mice is shown in Table V . In serum, about a hundred-fold increase in TNF activity was observed with Mu-IFN-y, while only 40% increase was observed intratumorally with this BRM. Acute toxicity of Groups of five males C3H/He mice (25-27 g) received an intravenous injection of different amounts of BPV (3.5 x 10'0 to 8.5 x 1010 cells per mouse) or OK-432 (4.0 x 108 to 8.0 x 108 cells per mouse). On day 7 after the injection the 50%' lethal dose (LD50) was calculated by the method of Behren and Karber (1935) . The LD50 values for BPV and OK-432 were 6.8 x 10'0 cells per mouse (2.6 x 1012 cells kg-') and 5.0 x 108 cells per mouse (1.9 x 10'0 cells kg-'), respectively. In this paper, biological activities were measured following doses of 4 x 109 cells per mouse (1.5 x 10" cells kg-') of BPV and 3 x 108 cells per mouse (1.2 x 10'0 cells kg-') of OK-432.
Discussion
We previously reported that endogenous TNF activity was induced by a combination of various commercially available drugs as a primer and a trigger. That is to say, purified protein derivative (PPD) (Satoh et al., 1986a) , immune complex (Satoh et al., 1986b) , macrophage activating factor (Minagawa et al., 1988) , interferon-a, P, y and interleukin-2 (Satoh et al., 1986c) were used as the primer, and OK-432 (Satoh et al., 1986c) , Cholera vaccine (Minagawa et al., 1987) and BPV (Minagawa et al., 1988) were used as the trigger. We reported earlier (Minagawa et al., 1988 ) that intratumoral TNF activity was induced by a local BPV injection without a primer, and this resulted in a therapeutic effect.
In this paper, we have shown for the first time that high intratumoral TNF activity can be induced endogenously even by a systemic injection of BPV without primer (Figure 1 , Tables I-III) . One or two hours after i.v. injection of BPV to tumour-bearing mice, high intratumoral TNF activity was induced, whereas activity was not detected when OK-432 was used (Figure 1, Tables I and II) . This TNF-inducing pattern was observed in 3 different tumour cell lines. Since TNFaccumulation in the tumour sites can affect the therapeutic effect, high intratumoral TNF activity (as observed in Table  I ), especially following systemic treatment (as in Table II) , augers well for therapeutic experiments. Takahashi et al. (1988) reported that a cytotoxic factor was induced intratumorally by the i.v. injection of high doses (2 mg per mouse) of a mannoglucan prepared from Microellobosporia grisea: by the cytotoxic factor could not be induced in mice bearing Lewis lung carcinoma. Therefore, BPV may show a broader spectrum of TNF against a greater number of tumour species than this mannoglucan.
The test of neutralisation by anti-MuTNF-x Ab suggests that TNF activity assayed on L-929 cells in this paper would be that of TNF-m-type (Table III) .
TNF is thought to be released by migrating macrophages at the tumour site because TNF activity induced in tumour tissues by BPV is inhibited by anti-macrophage Ab (Table  IV) . It seems that the tissues have been already primed, because preliminary activation by IFN-y is not necessary for them to induce TNF (Table V) . This suggests that BPV can be effective by a single injection, and be adaptable for clinical use.
Antitumour therapeutic effect was found to correlate with the intratumoral TNF induction by i.v. injection of inducers (Figures 1-3) . We therefore believe that intratumoral TNF activity is a good predictor of therapeutic effect.
